Oregon has become one of the most closely watched places in the United States when it comes to legal access to psilocybin. But Oregon did not simply “legalize mushrooms.” Instead, the state created a regulated system that allows adults age 21 and older to access psilocybin services at licensed service centers under the supervision of trained facilitators. The program offers an unusual real-world example of what regulated psychedelic access can look like outside of a traditional clinical trial.

For states such as Minnesota, Oregon’s experience provides an opportunity to examine both the potential benefits of psilocybin and the questions that remain about safety, effectiveness, cost, accessibility, and regulation.

What did Oregon actually Legalize?

Oregon voters approved Measure 109 in 2020, creating the Oregon Psilocybin Services program. The program does not operate like a recreational cannabis market. Adults cannot simply walk into a dispensary, purchase psilocybin products, and take them home. Under Oregon’s regulated system, psilocybin products are manufactured and tested by licensed businesses and administered at licensed service centers.

A client generally goes through three stages:

1. Preparation — The client meets with a facilitator, reviews relevant health and safety information, discusses what to expect, and completes required paperwork.

2. Administration — The client consumes a regulated psilocybin product at a licensed service center and remains there for the required period while supported by a licensed facilitator.

3. Integration — Clients may participate in an optional follow-up session to discuss their experience and how they want to incorporate insights from it into their lives.

Importantly, Oregon’s system is not the same thing as conventional medical treatment. A person does not need a psychiatric diagnosis or a prescription to participate in Oregon Psilocybin Services.

WHY IS PSILOCYBIN BEING STUDIED?

Depression

Depression has been one of the most prominent areas of psilocybin research.

Clinical studies have found that psilocybin administered with psychological support can produce substantial reductions in depressive symptoms for some participants.

Research published in major medical journals has examined psilocybin for major depressive disorder and treatment-resistant depression, including studies in which improvements occurred relatively quickly following one or a small number of dosing sessions.

However, researchers continue to study how long these benefits last, which patients are most likely to benefit, and how psilocybin-assisted approaches compare with existing treatments over longer periods.

Psilocybin therapy also involves much more than simply consuming psilocybin. Preparation, supervision, psychological support, and follow-up have been important components of many clinical trials.

Alcohol and Other Substance-Use Disorders

Researchers are also studying whether psilocybin-assisted therapy could help people with certain substance-use disorders.

A randomized clinical trial involving people with alcohol use disorder found that participants receiving psilocybin-assisted psychotherapy experienced a lower percentage of heavy drinking days during the study period than participants who received an active placebo along with psychotherapy.

Other smaller studies have explored psilocybin-assisted approaches for tobacco addiction.

These results are promising but preliminary. Larger and longer-term studies are needed before researchers can determine exactly how effective psychedelic-assisted treatments may be for addiction and which patients are most likely to benefit.

The Experience May be Difficult

One misconception about psychedelic therapy is that the experience is necessarily pleasant. Psilocybin can produce dramatic changes in perception, emotions, sense of time, and sense of self. Some people describe deeply meaningful or positive experiences.

Others experience intense fear, anxiety, confusion, nausea, emotional distress, or paranoia.

These difficult experiences are one reason researchers and regulated programs place considerable emphasis on preparation, environment, screening, and supervision.

A challenging psychedelic experience does not automatically mean that someone has been harmed, but psychological distress during intoxication can be significant.

Physical Side Effects

Psilocybin can produce temporary physical effects.

Reported effects can include nausea, headache, dizziness, increased blood pressure, increased heart rate, fatigue, and changes in coordination.

For many healthy adults participating in controlled studies, serious medical complications have been uncommon. People with certain cardiovascular conditions or other medical concerns may face additional risks and should discuss those risks with an appropriate healthcare professional.

Mental Health Risks

One of the most important issues in psychedelic research is identifying people who may face greater psychological risks.

Many clinical trials exclude people with certain psychiatric histories, particularly individuals with personal or sometimes family histories of psychotic disorders or bipolar disorder.

Psilocybin can temporarily cause profound alterations in perception and thinking. There are concerns that psychedelics could trigger or worsen mania or psychosis in susceptible individuals.

Because clinical trials often screen out higher-risk participants, findings showing relatively good safety in research settings cannot automatically be generalized to everyone in the population.

Medication Interaction

Many people interested in psychedelic therapy already take antidepressants or other psychiatric medications.

Researchers are still examining how these medications interact with psilocybin. Someone considering psilocybin should not stop a prescribed medication simply to participate in psychedelic services without discussing the decision with the healthcare professional responsible for that medication.

What Oregon Can Tell us

Oregon offers something clinical trials cannot: information about how a regulated psilocybin system functions in the real world.

The state can collect information about licensed manufacturers, laboratories, facilitators and service centers while regulators gain experience overseeing an entirely new industry.

But Oregon’s program also has important limitations if the goal is to evaluate psilocybin as a medical treatment.

Oregon Psilocybin Services is not a clinical research program, and its service centers are not necessarily healthcare facilities. Facilitators have state-required training and licensing requirements, but they are not automatically physicians, psychologists, or therapists.

That distinction matters when interpreting what happens in Oregon.

The program can provide valuable information about regulation, safety practices, consumer demand and implementation. It cannot by itself establish whether psilocybin is an effective treatment for a particular medical or psychiatric condition.

Access and Cost

One of the biggest practical questions surrounding regulated psychedelic services is accessibility.

A supervised psilocybin session can require many hours at a service center, in addition to preparation and possible integration sessions.

Clients may also pay for both the psilocybin product and the facilitator’s time.

Because these services generally are not covered like conventional medical care, cost can become a significant barrier.

This creates an important policy question for any state considering a similar model: even if regulated psychedelic services are legally available, who can realistically afford to use them?

What Can Minnesota Learn from Oregon

Minnesota does not need to duplicate Oregon’s system to learn from it.

Oregon provides policymakers, researchers, healthcare professionals and the public with a functioning example of regulated psilocybin access.

Its experience raises several questions Minnesota would need to consider if psychedelic policy changes are proposed in the future:

How should facilitators be trained?

What medical or psychological screening should occur?

What information should consumers receive before participating?

How should adverse events be reported?

Should psychedelic services operate primarily as healthcare, wellness services, or something else?

How can regulators protect consumers without making legal services so expensive that only wealthy clients can access them?

And perhaps most importantly, how should states distinguish between promising scientific research and claims that go beyond what the evidence currently supports?

SOURCES:

Oregon Health Authority — Oregon Psilocybin Services

U.S. Food and Drug Administration — Information regarding investigational psychedelic drugs and clinical research

National Institute on Drug Abuse (NIDA) — Psilocybin and psychedelic drug research

Johns Hopkins Center for Psychedelic and Consciousness Research

Journal of the American Medical Association (JAMA) / JAMA Psychiatry — Clinical research involving psilocybin and major depressive disorder

The New England Journal of Medicine — Research comparing psilocybin with established approaches to depression treatment

NYU Grossman School of Medicine — Research involving psilocybin, alcohol use disorder, and psychiatric applications